Abstract

Despite enormous progress in fundamental knowledge in neuroscience, no revolutionary therapies in psychiatry (and neurology) have emerged in the past ten years. Most drugs alleviate symptoms, rather than restoring the 'set point' of brain function from a pathological position to a more normal one. We propose a hypothesis-driven, systems-level approach to drug discovery and development that is based on pathophysiology and which uses new animal models.

Author affiliations

1. Michael Spedding is Deputy Director of Research for Servier, Institut de Recherches Internationales Servier (IRIS), 11 rue des Moulineaux, Suresnes 92150, France.
2. Thérèse Jay is a senior scientist at INSERM, E0117 INSERM Paris-5, Hôpital Ste Anne, Bât. Paul Broca, 2 ter rue déAlésia, 75014 Paris, France.
3. Jorge Costa e Silva is Professor of Psychiatry t The International Center for Mental Health Policy, New York University Medical School, New York, New York, USA.
4. Laurent Perret is President of Research and Development for Servier, Institut de Recherches Internationales Servier (IRIS), Courbevole 92415, France.

Correspondence to: Michael Spedding¹ Email: michael.spedding@fr.netgrs.com

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.